

EUROPEAN PATENT APPLICATION

Application number: **88115482.7**

Int. Cl.4: **C07D 215/38 , C07D 401/04**

Date of filing: **21.09.88**

Priority: **24.09.87 JP 239348/87**

Date of publication of application:
29.03.89 Bulletin 89/13

Designated Contracting States:
CH DE ES FR GB IT LI


Applicant: **SS PHARMACEUTICAL CO., LTD.**
2-12-4 Nihonbashi Hama-cho Chuo-ku
Tokyo(JP)

Inventor: **Konno, Fujiko**
1143, Nanpeidai
Narita-shi Chiba-ken(JP)
Inventor: **Umehara, Norimitsu**
1000-4, Kamiyasumatsu
Tokorozawa-shi Saitama-ken(JP)
Inventor: **Matsuda, Hideaki**
2-29-8, Higashiabiko
Abiko-shi Chiba-ken(JP)
Inventor: **Katori, Tatsuhiko**
3081-11, Fudawa Tone-machi
Kitasouma-gun Ibaraki-ken(JP)

Representative: **Wächtershäuser, Günter, Dr.**
Tal 29
D-8000 München 2(DE)

Quinoline derivatives.

A quinoline derivative represented by the following formula is disclosed.



wherein R₁ represents a hydrogen atom or an alkyl group which may contain a substituent and R₂ represents an alkyl group which may contain a substituent, or R₁ and R₂ in combination with each other and with the adjacent nitrogen atom form a ring which may contain a nitrogen atom other than said adjacent nitrogen atom, an oxygen atom, or a substituent, and R₃ represents a cyano group, a carbamoyl group, or a lower alkoxy carbonyl group. The compound exhibits superior cardiotonic activity and vasodilative activity, and thus is effective as a medicine.

QUINOLINE DERIVATIVES

BACKGROUND OF THE INVENTIONField of the Invention:

This invention relates to a novel quinoline derivative, and, more particularly, to a novel quinoline derivative which is useful as a medicine.


Description of the Background:

There are many quinoline derivatives known in the art. Among them, di-substituted quinoline derivatives having a pharmaceutical activity are quinophene having analgesic or antiphlogistic activities, dibucaine hydrochloride possessing anaesthetic activity, chloroquine phosphate, pentaquine phosphate and quinine used as an antimalarial agent, and quinidine as an antiarrhythmic agent. There has been, however, no knowledge surfaced about a pharmaceutical effect of 5,8-di-substituted quinoline derivatives.

The present inventors have synthesized various 5,8-disubstituted quinoline derivatives to study their pharmaceutical effects, and found that the novel compound represented by the following formula (I) exhibited a strong cardiotonic or vasodilative activity and was useful as a medicine for coronary disease treatment. Such a finding has led to the completion of this invention.

SUMMARY OF THE INVENTION

Accordingly, an object of the present invention is to provide a quinoline derivative represented by the following formula (I):



(I)


wherein R₁ represents a hydrogen atom or an alkyl group which may contain a substituent and R₂ represents an alkyl group which may contain a substituent, or R₁ and R₂ in combination with each other and with the adjacent nitrogen atom form a ring which may contain a nitrogen atom other than said adjacent nitrogen atom, an oxygen atom, or a substituent, and R₃ represents a cyano group, a carbamoyl group, or a lower alkoxy carbonyl group.

Other objects, features and advantages of the invention will hereinafter become more readily apparent from the following description.

DETAILED DESCRIPTION OF THE INVENTION AND PREFERRED EMBODIMENTS

Desirable alkyl groups represented by R₁ and R₂ in formula (I) are those having 1 to 12 carbon atoms. Given as substituents for these alkyl groups are, for example, hydroxyl groups, amino groups, alkylamino groups, dialkylamino groups, morpholino groups, ureido groups which may be substituted with alkyl groups,


acyloxy groups, such as alkanoyloxy groups or aroyloxy groups, and the like. The alkyl groups have one or more of these substituents. Also, given as example of rings formed by R₁ and R₂ in combination are pyrrolidine, piperidine, piperazine, morpholine, pyrrole, imidazole, pyridine, pyrimidine, and the like. They may be substituted with the above-mentioned alkyl group which may have substituent groups or with the above-mentioned substituent groups for the alkyl group. A typical example of a piperazine ring formed by R₁ and R₂ in combination is that represented by formula:



wherein R₄ represents an alkyl group which may have a substituent, an aralkyl group such as a phenyl alkyl group, an aryl group such as a phenyl or naphthyl group, an acyl group such as an alkanoyl, aroyl, or heteroaroyl group, a formyl group, or a carbamoyl group which may be substituted with an alkyl group.

The compound of formula (I) of this invention can be prepared, for example, according to the following processes.

Process 1:



wherein X represents a halogen atom and R₁ and R₂ have the same meanings as defined above.


An amino compound (III) is reacted with 5-halogeno-8-nitroquinoline (II) to produce 5-substituted-8-nitroquinoline (IV), which is reduced into 5-substituted-8-aminoquinoline (V). The amino group of this compound is then converted into a cyano group to produce 5-substituted-8-quinolinecarbonitrile (VI).

In these reactions, the amination is carried out by using 2 to 8 mols of the compound (III) per 1 mol of the compound (II) and by stirring the reaction mixture for 1 to 20 hours at room temperature or at a refluxing point of the solvent used. Methanol, ethanol, ethoxyethanol, methoxyethanol, dioxane, dimethylformamide, pyridine, or the like can be used as a solvent. After the reaction, the solvent is removed by evaporation, and the target compound (VI) is obtained by extracting the residue with a solvent such as chloroform, followed by purification of the extract with silica gel column chromatography or by recrystallization.

The reduction of compound (IV) into compound (V) can be effected either catalytically or by the use of a metal and an acid. The catalytic reduction is performed in a solvent such as alcohol or the like in the presence of a catalyst and in a hydrogen atmosphere at room temperature while stirring the reaction

mixture. Palladium-carbon, palladium black, platinum black, or the like is used as a catalyst. The reduction by a metal and an acid is implemented using iron, zinc, tin, stannous chloride, or the like as a metal, and hydrochloric acid or the like as an acid. The reaction is carried out at a temperature from room temperature to 100° C for 1 to 5 hours. After completion of the reaction, the reaction mixture is neutralized with an alkali, followed by extraction with ethyl acetate or the like to obtain compound (V). The conversion of the amino group of compound (V) into cyano group is carried out by first producing a diazonium salt using sodium nitrite, isoamyl nitrite, or the like, and then by charging the diazonium salt into a cyanizing agent such as an aqueous solution of cuprous cyanide and stirring the mixture at 0 to 70° C for several hours. The mixture is extracted with a solvent such as ethyl acetate and the extract is subjected to silica gel column chromatography or recrystallization to obtain compound (Ia) in a purified form.


Process 2:



wherein X represents a halogen atom and R₁ and R₂ have the same meanings as defined above.


5-Halogeno-8-nitroquinoline (II) is reduced into 5-halogeno-8-aminoquinoline (VI), which is cyanized into compound (VII). The compound (VII) is then reacted with an amino compound (III) to produce the quinoline derivative (Ia).

The reduction is carried out using a metal and an acid. Iron, zinc, tin, stannous chloride, or the like is used as a metal, and hydrochloric acid or the like is used as an acid. The reaction is carried out at a temperature of from room temperature to 100° C for 1 to 5 hours. After completion of the reaction, the reaction mixture is neutralized by an alkali, followed by extraction with ethyl acetate or the like to produce compound (VI). This compound (VI) is converted into compound (VII) in the same manner as in Process 1, followed by amination of compound (VII) in the same manner as in Process 1 to obtain compound (Ia).


Process 3:

wherein X represents a halogen atom and R₁ and R₂ have the same meanings as defined above.

5-Halogeno-8-quinolinecarbonitrile (VII) is hydrolyzed into 5-halogeno-8-quinolinecarboxamide (VIII), which is reacted with an amino compound (III) to produce the quinoline derivative (Ib). The hydrolysis is implemented according to a conventional method, e.g. by dissolving compound (VII) into a solvent and stirring the mixture in the presence of a base and 30% hydrogen peroxide at a temperature of from room temperature to 50° C. It is desirable to use an alcohol such as methanol, ethanol, or the like as a solvent and an inorganic base such as sodium hydroxide, potassium hydroxide, or the like as a base. Amination is effected to 5-halogeno-8-quinolinecarboxamide (VIII) thus obtained in the same manner as Process 1 to produce compound (Ib).


Process 4:

wherein R₁ and R₂ have the same meanings as defined above. 5-substituted-8-quinolinecarboxamide (Ib) can be produced by the hydrolysis of 5-substituted-8-quinolinecarbonitrile (Ia). The reaction is carried out exactly in the same manner as the hydrolysis reaction of Process 3.

Process 5:

wherein X represents a halogen atom, R₅ represents a lower alkyl group, and R₁ and R₂ have the same meanings as defined above.

5-Halogeno-8-quinolinecarboxamide (VIII) is esterified into 5-halogeno-8-quinolinecarboxylic acid ester (IX). The quinoline derivative (Ic) is produced by the reaction of compound (IX) and an amino compound (III). The esterification of compound (VIII) is implemented according to a known method, e.g. by stirring the mixture of compound (VIII) and an anhydrous alcohol in the presence of an acid catalyst at a temperature from room temperature to the refluxing point of the alcohol used for several hours. Use of a strong acid such as hydrochloric acid or sulfuric acid is desirable. 5-Halogeno-8-quinolinecarboxylic acid ester (IX) thus obtained is reacted with an amino compound (III) according to the same manner as in Process 1 to produce compound (Ic).

Process 6:

wherein R₁ and R₂ have the same meanings as defined previously.

5-Substituted-8-quinolinecarboxylic acid ester (Ic) is produced by the esterification of 5-substituted-8-quinolinecarboxamide (Ib).

The reaction is performed in the same manner as in the reaction of Process 5.

The quinoline derivative (I) produced in either of the processes illustrated above can be converted by a conventional method, as required, into an inorganic salt such as hydrochloride, hydrobromide, nitrate, sulfate, or the like, or into an organic salt such as acetate, citrate, maleate, fumarate, lactate, methane sulfonate, or the like.

Pharmaceutical actions of the compounds of this invention were tested.

(1) Cardiotonic Activity

5

Hearts of Hartley guinea pigs (male, weight: 400 - 600 g) were taken out and mus'culi papilla'ris ventric'uri dex'tri was enucleated from each heart in Krebs-bicarbonate solution. This test specimen was suspended in a 20 ml bath containing Krebs-bicarbonate solution at 32 °C aerated with a 95% O₂ and 5% CO₂ mixed gas with its mus'culi papilla'ris base being fixed at a static tension of 0.5 g. A transparietal electroversion (voltage: twice of the threshold voltage; 0.5 Hz, 3 msec.) was applied to measure the contraction force.

10

After stabilizing the test specimen, a test compound dissolved into 1 N hydrochloric acid and diluted to 10⁻⁵ g/ml with physiological saline was administered. Maximum rate of the change (Δ %) in contraction force after administration vs. before administration of the test compound was taken as a standard for the cardiotonic activity (contraction increase effect) of the compound. The results are shown in Table 1, in which compound numbers designate those shown in Table 3.

15

TABLE 1

20

Compound No.	Contraction Increase (%)
2	36.7
4	38.8
7	46.4
13	39.5
20	35.0
21	28.5
22	35.0

25

30

(2) Vasodilative Activity

35

A bastard, male, adult dog weighing about 10 kg was respiration under narcosis. Its right arteria femola'lis was exposed with administration of heparin. An artificial circuit containing on a electro-magnetic blood flowmeter probe was established to measure the blood flow through the right arteria femola'lis.

40

The change (%) in blood flow before and after administration of the test compound to the circuit in an amount of 1 to 300 μ g (the maximum dose that does not affect the general blood pressure) was calculated. The value was taken as an ED₁₀₀ (A). As a control, the corresponding ED₁₀₀ value (B) for papaverine.HCl in an amount of 1 to 300 μ g (the maximum dose that does not affect the general blood pressure) was determined for comparison. Vasodilative activities of the compounds were determined as the ratio B/A. The results are shown in Table 2, in which compound numbers designate those shown in Table 3.

45

TABLE 2

50

Compound No.	Vasodilative Activity
15	0.86
21	0.36
35	0.56
44	3.70
papaverine.HCl	1.00

55

As demonstrated by the above experiment the compound of this invention exhibits superior cardiotonic activity and vasodilative activity, and thus is effective as a medicine.

Other features of the invention will become apparent in the course of the following description of the exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.

5

EXAMPLES

10 Example 1

5-Morpholino-8-nitroquinoline, 3.90 g, was dissolved into 30 ml of water and 30 ml of hydrochloric acid. To this mixture 10.2 g of stannous chloride dihydrate was added and the mixture was heated on a water bath under stirring for 1 hour. After cooling, the mixture was neutralized with potassium carbonate and
 15 extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate. Ethyl acetate was evaporated to produce 1.83 g (yield: 53%) of 8-amino-5-morpholinoquinoline. This compound was dissolved into 10 ml of water and 6 ml of concentrated HCl, and to the solution an aqueous solution containing 0.62 g of sodium nitrite was added dropwise while stirring at - 15 °C. The diazonium salt thus obtained was neutralized with sodium bicarbonate, and resulting product was added at 0 °C into an aqueous solution of
 20 cuprous cyanide (prepared from 2.0 g of cuprous chloride and 3.4 g of potassium cyanide). The mixture was stirred at the same temperature for 1 hour, then at 70 °C for 30 minutes to complete the reaction. The reaction mixture was extracted with ethyl acetate and the extract was dried over anhydrous sodium sulfate. Ethyl acetate was evaporated and the residue was refined by column chromatography on silica gel using a chloroform-n-hexane (3:2) mixed solvent as an eluent. The crystals thus obtained were recrystallized from
 25 ethanol to yield 0.12 g (yield: 6.2%) of 5-morpholino-8-quinolinecarbonitrile (Compound No. 13)

Example 2

30 5-Chloro-8-nitroquinoline, 5 g, was reduced, diazonized, and cyanized in the same manner as in Example 1 to produce 2.62 g (yield: 58%) of 5-chloro-8-quinolinecarbonitrile. A mixture of 1.88 g of 5-chloro-8-quinolinecarbonitrile thus prepared and 7.10 g of pyrrolidine was dissolved into 30 ml of 2-ethoxyethanol and the solution was heated under reflux for 3 hours. The solvent was evaporated, and the residue, after addition of water, was extracted with chloroform. The extract was washed with water and dried
 35 over anhydrous sodium sulfate. Chloroform was evaporated, and the residue was refined by column chromatography on silica gel using a chloroform-methanol (95:5) mixed solvent as an eluent. The crystals thus obtained were recrystallized from ethanol to yield 1.54 g (yield: 69%) of 5-pyrrolidino-8-quinolinecarbonitrile (Compound No. 7).

40

Example 3

5-Chloro-8-quinolinecarbonitrile, 0.50 g, and imidazole, 1.80 g, were dissolved into 30 ml of pyridine. To the solution 0.36 g of anhydrous potassium carbonate was added and the mixture was heated under reflux
 45 for 8 hours. After separating indissolved substance by filtration, the solvent was evaporated and the residue was refined by column chromatography on silica gel using chloroform as an eluent. The crystals obtained were recrystallized from ethanol to yield 0.35 g (yield: 60%) of 5-imidazolyl-8-quinolinecarbonitrile (Compound No. 20).

50

Example 4

To 0.8 g of 5-morpholino-8-quinolinecarbonitrile (Compound No. 13) 60 ml of methanol was added and the mixture was stirred at 0 °C with further addition of an aqueous solution of 0.47 g of potassium hydroxide
 55 and then 5 ml of 30% hydrogen peroxide aqueous solution. The mixture was heated at 40 to 50 °C for 16 hours with stirring. After evaporation of the solvent, saturated sodium chloride aqueous solution was added to the residue, which was extracted with chloroform, and the extract was dried over anhydrous sodium sulfate. Chloroform was evaporated, and the residue was refined by column chromatography on silica gel

using chloroform as an eluent. The crystals thus obtained were recrystallized from ethanol to yield 0.48 g (yield: 56%) of 5-morpholino-8-quinolinecarboxamide (Compound No. 22).

5 Example 5

To 0.17 g of 5-morpholino-8-quinolinecarboxamide (Compound No. 22) 10 ml of anhydrous ethanol and 2 ml of concentrated sulfuric acid were added, and the mixture was heated under reflux. The solvent was evaporated and the residue was neutralized with saturated aqueous solution of sodium bicarbonate. After
10 extraction with ethyl acetate, the extract was washed with saturated aqueous solution of sodium chloride, and dried over anhydrous sodium sulfate. Ethyl acetate was evaporated, and the residue was refined by column chromatography on silica gel using chloroform-n-hexane (3:2) as an eluent. The crystals thus obtained were recrystallized from chloroform-ether to yield 0.16 g (yield: 85%) of ethyl 5-morpholino-8-quinolincarboxylate (Compound No. 23).

15

Example 6

Compounds listed in Table 3 were prepared according to the same manner as Examples 1 to 5. Table
20 3 also lists the compounds prepared in Examples 1 to 5.

25

30

35

40

45

50

55

TABLE 3



Compd. No.	$\begin{array}{c} R_1 - N \\ \diagup \quad \diagdown \\ R_2 \end{array}$	R ₃	Melting Point (°C)	NMR δ (ppm in CDCl ₃ * : in CD ₃ COO ** : DMSO-d ₆)
1	-NHCH ₂ CH ₂ OH	CN	199-200	3.51 (t, 2H), 3.87 (t, 2H), 6.65 (d, 1H), 7.48 (dd, 1H), 7.95 (d, 1H), 8.61 (dd, 1H), 8.88 (dd, 1H). *
2	-NHCH ₂ CH ₂ CH ₂ OH	CN	202.5-203	1.73-2.26 (m, 2H), 3.26-4.00 (m, 4H), 6.56 (d, 1H), 7.43 (dd, 1H), 7.89 (d, 1H), 8.45 (dd, 1H), 8.86 (dd, 1H). *
3	-NHCH ₂ CH ₂ OAc	CN	204-205	2.00 (s, 3H), 3.34 (s, 1H), 3.40-3.80 (m, 2H), 4.28 (t, 2H), 6.70 (d, 1H), 7.55 (dd, 1H), 8.00 (d, 1H), 8.78 (dd, 1H), 8.98 (dd, 1H).
4	-NHCH ₂ CH ₂ CH ₂ OAc	CN	149.5-150.5	1.67-2.33 (m, 5H), 3.26-3.66 (m, 2H), 4.26 (t, 2H), 5.60 (br, 1H), 6.55 (d, 1H), 7.40 (dd, 1H), 7.89 (d, 1H), 8.26 (dd, 1H), 8.97 (dd, 1H).
5	-N(CH ₂ CH ₂ OH) ₂	CN	140-141	3.40-3.60 (m, 4H), 3.70-4.00 (m, 4H), 6.70 (d, 1H), 7.50 (dd, 1H), 7.94 (d, 1H), 8.60 (dd, 1H), 8.88 (dd, 1H). *
6	-NHCH ₂ CH ₂ N(CH ₃) ₂	CN	125-127	2.31 (s, 6H), 2.70 (t, 2H), 3.18-3.40 (m, 2H), 6.02 (br, 1H), 6.49 (d, 1H), 7.41 (dd, 1H), 7.91 (d, 1H), 8.20 (dd, 1H), 9.00 (dd, 1H)
7		CN	176-178	1.75-2.30 (m, 4H), 3.20-3.80 (m, 4H), 6.55 (d, 1H), 7.30 (dd, 1H), 7.80 (d, 1H), 8.55 (dd, 1H), 8.90 (dd, 1H).
8		CN	155-155.5	1.50-2.40 (m, 5H), 3.20-4.30 (m, 5H), 6.90 (d, 1H), 7.35 (dd, 1H), 7.88 (d, 1H), 8.50 (dd, 1H), 8.90 (dd, 1H).

TABLE 3 (continued)









Compd. No.	$\begin{array}{c} R_1 \\ \diagup \\ N \\ \diagdown \\ R_2 \end{array}$	R ₃	Melting Point (°C)	NMR δ (ppm) in CDCl ₃ * : in CD ₃ COO ** : DMSO-d ₆
9		CN	— Oil substance	1.89 (s, 3H), 1.67-2.66 (m, 4H), 3.17-4.50 (m, 5H), 7.04 (d, 1H), 7.40 (dd, 1H), 7.90 (d, 1H), 8.50 (dd, 1H), 9.00 (dd, 1H).
10		CN	112-113.5	1.50-2.00 (m, 6H), 3.00-3.30 (m, 4H), 7.05 (d, 1H), 7.50 (dd, 1H), 8.05 (d, 1H), 8.45 (dd, 1H), 9.05 (dd, 1H).
11		CN	184-185	1.50-2.50 (m, 5H), 2.66-3.69 (m, 4H), 4.00 (br, 1H), 7.00 (d, 1H), 7.40 (dd, 1H), 7.90 (d, 1H), 8.40 (dd, 1H), 8.92 (dd, 1H).
12		CN	147-148.5	1.56-2.40 (m, 7H), 2.83-3.66 (m, 4H), 4.83-5.30 (m, 1H), 7.06 (d, 1H), 7.50 (dd, 1H), 8.03 (d, 1H), 8.40 (dd, 1H), 9.00 (dd, 1H).
13		CN	180-181	3.05-3.40 (m, 4H), 3.80-4.50 (m, 4H), 7.10 (d, 1H), 7.50 (dd, 1H), 8.10 (d, 1H), 8.50 (dd, 1H), 9.05 (dd, 1H).
14		CN	132-134	3.20 (s, 8H), 7.15 (d, 1H), 7.55 (dd, 1H), 8.10 (d, 1H), 8.50 (dd, 1H), 9.05 (dd, 1H).
15		CN	159-160	2.43 (s, 3H), 2.50-3.00 (m, 4H), 3.00-3.40 (m, 4H), 7.06 (d, 1H), 7.45 (dd, 1H), 7.95 (d, 1H), 8.45 (dd, 1H), 9.00 (dd, 1H).
16		CN	150-151	2.60-2.90 (m, 6H), 3.10-3.30 (m, 4H), 3.50-3.90 (t, 2H), 7.10 (d, 1H), 7.50 (dd, 1H), 8.05 (d, 1H), 8.50 (dd, 1H), 9.05 (dd, 1H).

TABLE 3 (continued)

Compd. No.	$\begin{array}{c} R_1 \diagup N \\ \diagdown R_2 \end{array}$	R ₃	Melting Point (°C)	NMR δ (ppm) in CDCl ₃ * : in CD ₃ COO ** : DMSO-d ₆
17		CN	189-191	3.00-3.40 (m, 4H), 3.50-4.00 (m, 4H), 7.10 (d, 1H), 7.55 (dd, 1H), 8.05 (d, 1H), 8.20 (s, 1H), 8.50 (dd, 1H), 9.05 (dd, 1H).
18		CN	188-190	2.20 (s, 3H), 3.00-3.40 (m, 4H), 3.60-4.10 (m, 4H), 7.05 (d, 1H), 7.55 (dd, 1H), 8.05 (d, 1H), 8.50 (dd, 1H), 9.05 (dd, 1H).
19		CN	172-173	1.09 (s, 3H), 1.23 (s, 3H), 2.63-3.00 (m, 5H), 3.66-4.07 (m, 4H), 7.03 (d, 1H), 7.50 (dd, 1H), 8.00 (d, 1H), 8.43 (dd, 1H), 9.00 (dd, 1H).
20		CN	210-212	7.23-7.50 (m, 2H), 7.50-7.95 (m, 3H), 8.00-8.40 (m, 2H), 9.15 (dd, 1H).
21		CONH ₂	229-231	1.72 (s, 2H), 1.72-2.10 (m, 4H), 3.35-3.80 (m, 4H), 6.84 (d, 1H), 7.28 (dd, 1H), 8.64 (dd, 1H), 8.68 (d, 1H), 8.80 (dd, 1H).
22		CONH ₂	243-245	3.00-3.30 (m, 4H), 3.80-4.10 (m, 4H), 6.10 (br, 2H), 7.20 (d, 1H), 7.45 (dd, 1H), 8.60 (dd, 1H), 8.80 (d, 1H), 8.90 (dd, 1H).
23		CO ₂ Et (Hydrochloride)	103-105	1.40 (t, 3H), 2.90-3.30 (m, 4H), 3.80-4.20 (m, 4H), 4.50 (q, 2H), 7.05 (d, 1H), 7.40 (dd, 1H), 8.00 (d, 1H), 8.45 (dd, 1H), 9.00 (dd, 1H).
24		CN	221.5-222.5	3.05 (d, 3H), 5.20 (br, 1H), 6.55 (dd, 1H), 7.45 (dd, 1H), 8.00 (d, 1H), 8.15 (dd, 1H), 9.04 (dd, 1H).

TABLE 3 (continued)

Compd. No.	$ \begin{array}{c} R_1 \text{---} N \\ \diagup \quad \diagdown \\ R_2 \end{array} $	R ₃	Melting Point (°C)	NMR δ (ppm in CDCl ₃ * : in CD ₃ COO ** : DMSO-d ₆)
25	-NH-C ₄ H ₉ -n	CN	199.5-200	1.00 (t, 3H), 1.20-2.00 (m, 4H), 3.20-3.45 (m, 2H), 5.05 (br, 1H), 6.55 (d, 1H), 7.44 (dd, 1H), 7.96 (d, 1H), 8.20 (dd, 1H), 9.05 (dd, 1H).
26	-NHCH(CH ₃)CH ₂ OH	CN	212-214	1.35 (d, 3H), 3.60-4.00 (m, 4H), 6.59 (d, 1H), 7.50 (dd, 1H), 8.00 (d, 1H), 8.55 (dd, 1H), 9.00 (dd, 1H). *
27	-NHCH ₂ CH(OH)CH ₂ OH	CN	188-190.5	3.40-3.80 (m, 4H), 3.90-4.15 (m, 1H), 6.71 (d, 1H), 7.55 (dd, 1H), 8.00 (d, 1H), 8.70 (dd, 1H), 8.96 (dd, 1H). *
28	-NH(CH ₂) ₄ OH	CN	176-178	1.40-2.00 (m, 4H), 3.20-3.44 (m, 2H), 3.65 (t, 2H), 6.50 (d, 1H), 7.50 (dd, 1H), 7.90 (d, 1H), 8.50 (dd, 1H), 8.90 (dd, 1H). *
29	-NH(CH ₂) ₆ OH	CN	134.5-135.5	1.00-2.00 (m, 8H), 3.20-3.50 (m, 2H), 3.50-3.80 (m, 2H), 6.53 (d, 1H), 7.40 (dd, 1H), 7.90 (d, 1H), 8.24 (dd, 1H), 9.00 (dd, 1H). *
30	-NH(CH ₂) ₃ NH ₂	CN	154-156	2.00 (q, 2H), 2.95 (t, 2H), 3.45 (t, 2H), 6.59 (d, 1H), 7.50 (dd, 1H), 7.98 (d, 1H), 8.60 (dd, 1H), 9.00 (dd, 1H). *
31	$ \begin{array}{c} \text{---NHCH}_2\text{CHCH}_2\text{NH}_2 \\ \\ \text{OH} \end{array} $	CN	188.5-200	2.60-2.75 (m, 2H), 2.80-3.90 (m, 6H), 6.65 (d, 1H), 7.40-7.80 (dd, br, 2H), 7.90 (d, 1H), 8.75 (dd, 1H), 8.95 (dd, 1H). **
32	-NHCH ₂ CH(OH)Ph	CN	215-216	3.45-3.64 ((dd, 2H), 5.00-5.20 (dd, 1H), 6.65 (d, 1H), 7.40-7.65 (m, 6H), 7.96 (d, 1H), 8.50 (dd, 1H), 9.02 (dd, 1H). *

TABLE 3 (continued)






Compd. No.	$\begin{array}{c} R_1 \\ \diagup \\ N \\ \diagdown \\ R_2 \end{array}$	R ₃	Melting Point (°C)	NMR δ (ppm in CDCl ₃ * : in CD ₃ COO ** : DMSO-d ₆)
33	-NHCH ₂ Ph	CN	178-179	4.55 (d, 2H), 5.50 (t, 1H), 7.24-7.50 (m, 6H), 6.55 (d, 1H), 7.90 (d, 1H), 8.24 (dd, 1H), 9.00 (dd, 1H).
34	-NH(CH ₂) ₃ NHCON(CH ₃) ₂	CN	200-202	1.70-2.10 (m, 2H), 2.20 (s, 1H), 2.92 (s, 6H), 3.20-3.55 (m, 5H), 6.50 (d, 1H), 7.45 (dd, 1H), 7.90 (d, 1H), 8.60 (dd, 1H), 8.96 (dd, 1H). *
35	-N(CH ₃) ₂	CN	112-114	3.03 (s, 6H), 6.95 (d, 1H), 7.45 (dd, 1H), 7.95 (d, 1H), 8.50 (dd, 1H), 9.00 (dd, 1H).
36		CN	153-155	1.16 (t, 3H), 2.55 (q, 2H), 2.60-2.90 (m, 4H), 3.10-3.40 (m, 4H), 7.05 (d, 1H), 7.55 (dd, 1H), 8.05 (d, 1H), 8.50 (dd, 1H), 9.05 (dd, 1H).
37		CN	145-146	0.65-1.85 (m, 7H), 2.30-3.00 (m, 6H), 3.00-3.40 (m, 4H), 7.10 (d, 1H), 7.50 (dd, 1H), 8.05 (d, 1H), 8.45 (dd, 1H), 9.03 (dd, 1H).
38		CN	104-105.5	0.60-1.85 (m, 11H), 2.20-2.90 (m, 6H), 3.00-3.35 (m, 4H), 7.05 (dd, 1H), 7.45 (dd, 1H), 8.50 (dd, 1H), 9.03 (dd, 1H).
39		CN	231-233	3.10-3.60 (m, 8H), 6.80-7.30 (m, 6H), 7.50 (dd, 1H), 8.00 (d, 1H), 8.50 (dd, 1H), 9.00 (dd, 1H).
40		CN	171-173	2.70-3.00 (m, 4H), 3.00-3.35 (m, 4H), 3.38 (s, 2H), 3.67 (s, 8H), 7.10 (d, 1H), 7.50 (dd, 1H), 8.05 (d, 1H), 8.45 (dd, 1H).


TABLE 3 (continued)

Compd. No.	$\begin{array}{c} R_1 \\ \\ R_2 - N \end{array}$	R_3	Melting Point (°C)	NMR δ (ppm) in $CDCl_3$ * : in CD_3CO ** : DMSO- d_6
41		CN	214-216	2.92 (s, 6H), 3.05-3.35 (m, 4H), 3.35-3.73 (m, 4H), 7.10 (d, 1H), 7.50 (dd, 1H), 8.05 (d, 1H), 8.50 (dd, 1H), 9.03 (dd, 1H).
42		CN	211-213	3.00-3.40 (m, 4H), 3.70-4.20 (m, 4H), 3.94 (s, 6H), 6.83-7.20 (m, 4H), 7.50 (dd, 1H), 8.03 (d, 1H), 8.55 (dd, 1H), 9.03 (dd, 1H).
43		CN	223-226	3.38 (s, 8H), 6.90-7.50 (m, 5H), 7.15 (d, 1H), 7.50 (dd, 1H), 8.05 (d, 1H), 8.55 (dd, 1H), 9.08 (dd, 1H).
44		CONH ₂	198-200	2.43 (s, 3H), 2.50-2.80 (m, 4H), 3.00-3.30 (m, 4H), 6.10 (br, 1H), 7.20 (d, 1H), 7.45 (dd, 1H), 8.55 (dd, 1H), 8.75 (d, 1H), 8.90 (dd, 1H).
45		CONH ₂	179-181	1.45-2.15 (m, 6H), 2.95-3.25 (m, 4H), 6.10 (br, 2H), 7.15 (d, 1H), 7.45 (dd, 1H), 8.55 (dd, 1H), 8.75 (d, 1H), 8.90 (dd, 1H).
46		CONH ₂	226-228	1.60-2.30 (m, 4H), 2.65-3.10 (m, 2H), 3.20-3.50 (m, 2H), 3.70-4.00 (m, 1H), 7.25 (d, 1H), 7.55 (dd, 1H), 8.65 (ddd, 2H), 8.96 (dd, 1H). *
47		CONH ₂	211-213	1.80-2.15 (m, 2H), 3.48 (t, 2H), 3.80 (t, 2H), 6.68 (d, 1H), 7.44 (dd, 1H), 8.50 (dd, 1H), 8.60 (d, 1H), 8.88 (dd, 1H). *
48		CONH ₂	204-205	1.35 (d, 3H), 3.68-4.08 (m, 3H), 6.70 (d, 1H), 7.42 (dd, 1H), 8.56 (ddd, 2H), 8.88 (dd, 1H). *

TABLE 3 (continued)

Compd. No.	$\begin{array}{c} R_1 \\ \diagup \\ N \\ \diagdown \\ R_2 \end{array}$	R_3	Melting Point (°C)	NMR δ (ppm) in $CDCl_3$ * : in CD_3COO ** : $DMSO-d_6$
49	$-NHCH_2CH(OH)CH_2OH$	$CONH_2$	219-222	3.50 (d, 2H), 3.70 (d, 2H), 3.84-4.20 (m, 1H), 6.71 (d, 1H), 7.45 (dd, 1H), 8.55 (dd, 1H), 8.60 (d, 1H), 8.92 (dd, 1H). *
50	$-NHCH_3$	$CONH_2$	250-252	3.04 (d, 3H), 6.60 (d, 1H), 7.44 (dd, 1H), 8.48 (dd, 1H), 8.62 (d, 1H), 8.88 (dd, 1H). *
51	$-N(CH_3)_2$	$CONH_2$	185.5-186.5	2.93 (s, 6H), 7.10 (d, 1H), 7.42 (dd, 1H), 8.56 (dd, 1H), 8.76 (d, 1H), 8.88 (dd, 1H).
52	$-N(CH_2)_4-CHO$	$CONH_2$	230-231.5	2.75-3.30 (m, 6H), 3.55-4.00 (m, 4H), 7.24 (d, 1H), 7.56 (dd, 1H), 8.14 (s, 1H), 8.64 (dd, 1H), 8.76 (d, 1H), 8.98 (dd, 1H). *
53	$-N(CH_2)_4-CH_3$	$COOEt$	— Oily substance	1.43 (t, 3H), 2.43 (s, 3H), 2.56-2.84 (m, 4H), 3.04-3.30 (m, 4H), 4.48 (q, 2H), 7.09 (d, 1H), 7.40 (dd, 1H), 8.04 (d, 1H), 8.50 (dd, 1H), 9.04 (dd, 1H).
54	$-N(CH_2)_3-$	$COOEt$	— Oily substance	1.42 (t, 3H), 1.70-2.10 (m, 4H), 3.20-3.40 (m, 4H), 4.44 (q, 2H), 6.72 (d, 1H), 7.28 (dd, 1H), 8.05 (d, 1H), 8.52 (dd, 1H), 9.00 (dd, 1H).
55	$-NH(CH_2)_3-N(CH_2)_4-$	CN	158-159.5	1.75-2.15 (m, 2H), 2.40-2.80 (m, 6H), 3.24-3.52 (m, 2H), 3.60-4.00 (m, 4H), 6.41 (d, 1H), 7.40 (dd, 1H), 7.24-7.50 (br, 1H), 7.84 (d, 1H), 8.35 (dd, 1H), 9.00 (dd, 1H)
56	$-N(CH_3)_2$	$COOEt$	— Oily substance	1.43 (t, 3H), 2.93 (s, 6H), 4.50 (q, 2H), 7.02 (d, 1H), 7.40 (dd, 1H), 8.02 (d, 1H), 8.52 (dd, 1H), 9.04 (dd, 1H).


TABLE 3 (continued)

Compd. No.	$\begin{array}{c} R_1 \quad N \\ \diagdown \quad / \\ R_2 \end{array}$	R ₃	Melting Point (°C)	NMR δ (ppm in CDCl ₃ * : in CD ₃ OD ** : DMSO-d ₆)
57		COOEt	—	1.43 (t, 3H), 1.60-2.30 (m, 4H), 2.70-3.08 (m, 2H), 3.16-3.50 (m, 2H), 3.76-4.12 (m, 1H), 4.50 (q, 2H), 7.06 (d, 1H), 7.44 (dd, 1H), 8.01 (d, 1H), 8.48 (dd, 1H), 9.04 (dd, 1H).
58	-NHCH ₂ CH ₃	CN	220.5-222	1.43 (t, 3H), 3.40 (q, 2H), 6.56 (d, 1H), 7.44 (dd, 1H), 7.96 (d, 1H), 8.20 (dd, 1H), 9.04 (dd, 1H).
59	-NHCH ₂ CH ₃	CONH ₂	241-243	1.40 (t, 3H), 3.40 (q, 2H), 6.65 (d, 1H), 7.42 (dd, 1H), 8.53 (dd, 1H), 8.60 (d, 1H), 8.88 (dd, 1H). *

Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that the scope of the appended claims, the invention may be practiced otherwise than as specifically described herein.

Claims

1. A quinoline derivative represented by the following formula (I):



(I)

wherein R₁ represents a hydrogen atom or an alkyl group which may contain a substituent and R₂ represents an alkyl group which may contain a substituent, or R₁ and R₂ in combination with each other and with the adjacent nitrogen atom form a ring which may contain a nitrogen atom other than said adjacent nitrogen atom, an oxygen atom, or a substituent, and R₃ represents a cyano group, a carbamoyl group, or a lower alkoxycarbonyl group.



DOCUMENTS CONSIDERED TO BE RELEVANT			EP 88115482.7												
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)												
A	CHEMICAL ABSTRACTS, vol. 98, no. 1, January 3, 1983, Columbus, Ohio, USA KUMAR, V. VIJAYA et al. "Formation constants and thermodynamic parameters of iron(II) chelates with quinoline-8-carboxylic and quinoxaline-2-carboxylic acids and their substituted derivatives in aqueous ethanol medium." page 379, column 1, abstract no. 4 231x & Indian J. Chem., Sect. A 1982, 21A(7), 748-50 --	1	C 07 D 215/38 C 07 D 401/04												
P, A	CHEMICAL ABSTRACTS, vol. 109, no. 11, September 12, 1988, Columbus, Ohio, USA KONNO, FUJIKO et al. "Preparation of aminoquinoline derivatives as antiinflammatory agents and cardiotonics." page 720, column 1, abstract no. 93 064f & Jpn. Kokai Tokkyo Koho JP 63 54,363 [88 54,363] --	1	TECHNICAL FIELDS SEARCHED (Int. Cl.4) C 07 D 215/00 C 07 D 401/00												
The present search report has been drawn up for all claims															
Place of search VIENNA		Date of completion of the search 28-11-1988	Examiner HAMMER												
<table border="0"><tr><td>CATEGORY OF CITED DOCUMENTS</td><td>T : theory or principle underlying the invention</td></tr><tr><td>X : particularly relevant if taken alone</td><td>E : earlier patent document, but published on, or after the filing date</td></tr><tr><td>Y : particularly relevant if combined with another document of the same category</td><td>D : document cited in the application</td></tr><tr><td>A : technological background</td><td>L : document cited for other reasons</td></tr><tr><td>O : non-written disclosure</td><td>& : member of the same patent family, corresponding document</td></tr><tr><td>P : intermediate document</td><td></td></tr></table>				CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention	X : particularly relevant if taken alone	E : earlier patent document, but published on, or after the filing date	Y : particularly relevant if combined with another document of the same category	D : document cited in the application	A : technological background	L : document cited for other reasons	O : non-written disclosure	& : member of the same patent family, corresponding document	P : intermediate document	
CATEGORY OF CITED DOCUMENTS	T : theory or principle underlying the invention														
X : particularly relevant if taken alone	E : earlier patent document, but published on, or after the filing date														
Y : particularly relevant if combined with another document of the same category	D : document cited in the application														
A : technological background	L : document cited for other reasons														
O : non-written disclosure	& : member of the same patent family, corresponding document														
P : intermediate document															



DOCUMENTS CONSIDERED TO BE RELEVANT			EP 88115482.7
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)
A	<p>CHEMICAL ABSTRACTS, vol. 83, no. 23, December 8, 1975, Columbus, Ohio, USA</p> <p>HUGHES, JOHN L. et al. "Cardiovascular activity of aromatic guanidine compounds." page 37, column 2, abstract no. 188 388y</p> <p>& J. Med. Chem. 1975, 18(11), 1077-88</p> <p style="text-align: center;">--</p>	1	<p>TECHNICAL FIELDS SEARCHED (Int. Cl.4)</p>
A	<p>CHEMICAL ABSTRACTS, vol. 105, no. 13, September 29, 1986, Columbus, Ohio, USA</p> <p>DIONNE, GERVAIS et al. "Ligand-receptor interactions via hydrogen-bond formation. Synthesis and pharmacological evaluation of pyrrolo and pyrido analogs of the cardiotonic agent 7-hydroxycyclindole." page 668, column 2, abstract no. 114 943b</p> <p>& J. Med. Chem. 1986, 29(8), 1452-7</p> <p style="text-align: center;">----</p>	1	
The present search report has been drawn up for all claims			
Place of search VIENNA		Date of completion of the search 28-11-1988	Examiner HAMMER
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			